Keith is President and CEO of TissueGen, Inc. TissueGen is a medical device company whose patented technology enables creation of biodegradable polymer devices with unique drug delivery capabilities. TissueGen is focusing initial product development efforts on vascular stents. A prototype of TissueGen’s bioasbsorbable drug eluting peripheral vascular stent has completed it first preclinical trials.

Prior to joining TissueGen, Keith had 15 years experience with venture-backed biotechnology companies, preceded by 10 years in the medical diagnostics industry. He was the founding President/CEO of GeneScreen, building it into a $15 million, multi-location laboratory testing company in the field of DNA analysis. GeneScreen was sold to Orchid BioSciences in 2000 where Keith managed their Identity Genomics business to over $30 million. Keith’s experience includes leading six rounds of venture financing with GeneScreen and assisting in Orchid’s IPO, four acquisitions, and two divestitures. Prior to GeneScreen, Keith’s career began with Corning Medical and then Ciba Corning Diagnostics with 10 years in various management positions in information services, manufacturing and business management. He obtained his Master of Business Administration degree with distinction from Harvard School of Business in 1978.